SSA
MRNA icon

Schonfeld Strategic Advisors’s Moderna MRNA Stock Holding History

Schonfeld Strategic Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-150,000
Closed -$6.24M – 2389
2024
Q4 		$6.24M Buy
+150,000
New +$7.17M 0.04% 429
2023
Q1 		– Sell
-100,000
Closed -$152K – 2430
2022
Q4 		$152K Buy
+100,000
New +$16.4M ﹤0.01% 2077

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Schonfeld Strategic Advisors's MRNA Position: Q2 2026 in Review

Schonfeld Strategic Advisors sold out of Moderna (MRNA) in Q2 2026, closing a stake of 15,691 shares — an estimated $797K sold.

Schonfeld Strategic Advisors first reported a position in MRNA in Q1 2020 and held it in 19 quarters. The position peaked at $16.5M in Q2 2024. 783 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Schonfeld Strategic Advisors reported no remaining Moderna position as of Q2 2026 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 15,691 Moderna shares in Q2 2026, an estimated $797K.
  • Schonfeld Strategic Advisors first reported a position in Moderna in Q1 2020 and held it in 19 quarters.
  • Schonfeld Strategic Advisors's Moderna position peaked at $16.5M in Q2 2024.
  • 783 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.